COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

Molecular Analysis for Therapy Choice (MATCH)

Protocol No
Principal Investigator
Ben George
The purpose of this study is to test any good and bad effects of several different study drugs or drug combinations, each of which targets specific genetic changes found in some cancers. The first step is to determine if you can participate in this study (screening step). The purpose of this screening step is to perform tests on your tumor cells to find out if your cancer has a gene change or mutation targeted by one or more of the drugs used in this study. The tests done on your tumor are investigational, and are done for the purpose of assigning a treatment to a MATCH substudy. Approximately 3000 people will be biopsied and have their tumor tissue evaluated for this screening study. Participants in the screening study that have a biopsy result that matches a substudy will be invited to participate in a specific substudy. It is expected that approximately 35 participants will take part in each of the MATCH substudies. We anticipate that 15-20% of patients will have a mutation that can be matched with a treatment in this study.
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Participating Institutions
Froedtert Hospital